{"protocolSection": {"identificationModule": {"nctId": "NCT00989833", "orgStudyIdInfo": {"id": "D5890L00032"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Comparing Symbicort\u00ae As-Needed or Bricanyl As-Needed or Pulmicort\u00ae Once Daily + Bricanyl As-Needed in Asthma Patients", "officialTitle": "A Randomised, Double Blind, Placebo Controlled, Parallel-group Study With Use of Budesonide/Formoterol \"As-needed\", or Terbutaline \"As-needed\" or Regular Use of Budesonide + Terbutaline \"As-needed\", in Patients With Mild Intermittent Asthma", "acronym": "MIA"}, "statusModule": {"statusVerifiedDate": "2012-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-09"}, "primaryCompletionDateStruct": {"date": "2010-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-09-30", "studyFirstSubmitQcDate": "2009-10-05", "studyFirstPostDateStruct": {"date": "2009-10-06", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-08-22", "resultsFirstSubmitQcDate": "2012-07-06", "resultsFirstPostDateStruct": {"date": "2012-08-14", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-07-06", "lastUpdatePostDateStruct": {"date": "2012-08-14", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "1. The primary objective of this study is:\n\n   * To evaluate the magnitude of the protective effect of the combination of budesonide and formoterol on an as-needed basis compared to the use of terbutaline as-needed on exercise induced bronchoconstriction in adults and adolescents with mild intermittent asthma\n2. The secondary objectives of this study are:\n\n   * To evaluate the magnitude of the protective effect of the combination of budesonide and formoterol as-needed compared to regular once daily use of budesonide plus terbutaline as-needed on exercise induced bronchoconstriction in adults and adolescents with mild intermittent asthma\n   * To evaluate safety of budesonide/formoterol as-needed, terbutaline as-needed and regular use of budesonide + terbutaline as-needed as terms of adverse event"}, "conditionsModule": {"conditions": ["Exercise Induced Asthma"], "keywords": ["Exercise induced asthma", "Mild intermittent asthma", "Exercise induced bronchoconstriction"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 66, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "A", "type": "ACTIVE_COMPARATOR", "description": "budesonide 400yg + terbutaline 0.4 mg as-needed", "interventionNames": ["Drug: budesonide", "Drug: terbutaline"]}, {"label": "B", "type": "ACTIVE_COMPARATOR", "description": "placebo + terbutaline 0.4 mg as-needed", "interventionNames": ["Drug: terbutaline"]}, {"label": "C", "type": "ACTIVE_COMPARATOR", "description": "placebo + budesonide/formoterol 160/4.5 yg as-needed", "interventionNames": ["Drug: budesonide/formoterol"]}], "interventions": [{"type": "DRUG", "name": "budesonide", "description": "400 yg x 1", "armGroupLabels": ["A"], "otherNames": ["Pulmicort Turbuhaler"]}, {"type": "DRUG", "name": "terbutaline", "description": "0.4 mg as-needed", "armGroupLabels": ["A", "B"], "otherNames": ["Bricanyl Turbuhaler"]}, {"type": "DRUG", "name": "budesonide/formoterol", "description": "160/4.5 yg as-needed", "armGroupLabels": ["C"], "otherNames": ["Symbicort Turbuhaler"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percent Change in Maximum Post-exercise Forced Expiratory Volume in One Second (FEV1) Fall After 6 Weeks", "description": "FEV1", "timeFrame": "Baseline and Visit 6"}], "secondaryOutcomes": [{"measure": "Percent Change in Maximum Post-exercise FEV1 Fall After 3 Weeks", "description": "FEV1", "timeFrame": "Baseline and 3 weeks"}, {"measure": "Bronchial Responsiveness to Mannitol", "description": "Change in cumulative Mannitol dose in mg in patients with a positive mannitol provocation test at baseline (PD15)", "timeFrame": "Baseline and 6 weeks"}, {"measure": "Concentration of Exhaled Nitric Oxide", "timeFrame": "6 weeks"}, {"measure": "Use of as Needed Medication", "description": "Mean number of as needed inhalations taken before exercise", "timeFrame": "6 weeks"}, {"measure": "Asthma Control Measured by a 5-item Asthma Control Questionnaire (ACQ5)", "description": "Change in overall ACQ5. ACQ5 measures asthma control and a lower values shows a better asthma control, a higher value is worse. A decrease in the ACQ5 shows an improvement during the treatment period. Range of ACQ5 is 0-5, with 0 as the best value and 5 as the worst value. Further information at www.qoltech.co.uk.", "timeFrame": "Baseline e and 6 weeks"}, {"measure": "Diary Recording of Asthma Symptoms", "description": "Asthma symptoms during days with exercise", "timeFrame": "6 weeks"}, {"measure": "Number of Participants With an Adverse Event During the Study", "timeFrame": "6 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* History of exercise induced asthma\n* Maximum 4 asthmatic episodes per week requiring use of reliever medication\n\nExclusion Criteria:\n\n* No previous treatment with inhaled oral corticosteroids during the last month before randomisation\n* Suspected poor capability to follow instructions, ie to exercise 3-4 times a week", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Kjell Larsson, Professor", "affiliation": "AstraZeneca MC Sweden", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Georgios Stratelis", "affiliation": "AstraZeneca MC Sweden", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Oslo", "country": "Norway", "geoPoint": {"lat": 59.91273, "lon": 10.74609}}, {"facility": "Research Site", "city": "Trondheim", "country": "Norway", "geoPoint": {"lat": 63.43049, "lon": 10.39506}}, {"facility": "Research Site", "city": "Goteborg", "country": "Sweden", "geoPoint": {"lat": 57.70716, "lon": 11.96679}}, {"facility": "Research Site", "city": "Huddinge", "country": "Sweden", "geoPoint": {"lat": 59.23705, "lon": 17.98192}}, {"facility": "Research Site", "city": "Linkoping", "country": "Sweden", "geoPoint": {"lat": 58.41086, "lon": 15.62157}}, {"facility": "Research Site", "city": "Lulea", "country": "Sweden", "geoPoint": {"lat": 65.58415, "lon": 22.15465}}, {"facility": "Research Site", "city": "Lund", "country": "Sweden", "geoPoint": {"lat": 55.70584, "lon": 13.19321}}, {"facility": "Research Site", "city": "Skene", "country": "Sweden", "geoPoint": {"lat": 57.48995, "lon": 12.64196}}, {"facility": "Research Site", "city": "Stockholm", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}, {"facility": "Research Site", "city": "Uppsala", "country": "Sweden", "geoPoint": {"lat": 59.85882, "lon": 17.63889}}]}, "referencesModule": {"references": [{"pmid": "24092567", "type": "DERIVED", "citation": "Lazarinis N, Jorgensen L, Ekstrom T, Bjermer L, Dahlen B, Pullerits T, Hedlin G, Carlsen KH, Larsson K. Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax. 2014 Feb;69(2):130-6. doi: 10.1136/thoraxjnl-2013-203557. Epub 2013 Oct 3."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A standardized exercise test (ECT) with duration of 6 minutes, at approximately 90% of maximal aerobic capacity (as defined on Visit 1) was performed on a treadmill while breathing dry air on Visit 2. Patients with exercised induced bronchoconstriction (defined as fall in FEV1 \u2265 10% ) could be randomized on Visit 3.", "recruitmentDetails": "On Visit 1, a total of 189 patients, aged 12-67, were enrolled at 10 study sites in 2 countries: Sweden and Norway. Of 189 enrolled patients, 66 patients were randomized and allocated to study treatment on Visit 3 (7 patients in Norway and 59 patients in Sweden).", "groups": [{"id": "FG000", "title": "Budesonide/Terbutaline", "description": "Budesonide once daily and terbutaline before exercise and as needed"}, {"id": "FG001", "title": "Terbutaline", "description": "Placebo budesonide once daily and terbutaline before exercise and as needed"}, {"id": "FG002", "title": "Budesonide/Formoterol", "description": "Placebo budesonide once daily and budesonide/formoterol before exercise and as needed"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "22"}, {"groupId": "FG002", "numSubjects": "23"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "19"}, {"groupId": "FG002", "numSubjects": "21"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Incorrectly randomized", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Budesonide/Terbutaline", "description": "Budesonide once daily and terbutaline before exercise and as needed"}, {"id": "BG001", "title": "Terbutaline", "description": "Placebo budesonide once daily and terbutaline before exercise and as needed"}, {"id": "BG002", "title": "Budesonide/Formoterol", "description": "Placebo budesonide once daily and budesonide/formoterol before exercise and as needed"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "23"}, {"groupId": "BG003", "value": "66"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "12"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "18"}, {"groupId": "BG003", "value": "52"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "14"}, {"groupId": "BG003", "value": "30"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "36"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percent Change in Maximum Post-exercise Forced Expiratory Volume in One Second (FEV1) Fall After 6 Weeks", "description": "FEV1", "populationDescription": "The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Visit 6", "groups": [{"id": "OG000", "title": "Budesonide/Terbutaline", "description": "Budesonide once daily and terbutaline before exercise and as needed"}, {"id": "OG001", "title": "Terbutaline", "description": "Placebo budesonide once daily and terbutaline before exercise and as needed"}, {"id": "OG002", "title": "Budesonide/Formoterol", "description": "Placebo budesonide once daily and budesonide/formoterol before exercise and as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "21"}, {"groupId": "OG002", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.85", "spread": "6.50"}, {"groupId": "OG001", "value": "0.61", "spread": "10.92"}, {"groupId": "OG002", "value": "-5.24", "spread": "9.64"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change in Maximum Post-exercise FEV1 Fall After 3 Weeks", "description": "FEV1", "populationDescription": "The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and 3 weeks", "groups": [{"id": "OG000", "title": "Budesonide/Terbutaline", "description": "Budesonide once daily and terbutaline before exercise and as needed"}, {"id": "OG001", "title": "Terbutaline", "description": "Placebo budesonide once daily and terbutaline before exercise and as needed"}, {"id": "OG002", "title": "Budesonide/Formoterol", "description": "Placebo budesonide once daily and budesonide/formoterol before exercise and as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "21"}, {"groupId": "OG002", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.07", "spread": "5.56"}, {"groupId": "OG001", "value": "-1.19", "spread": "8.03"}, {"groupId": "OG002", "value": "-3.81", "spread": "8.68"}]}]}]}, {"type": "SECONDARY", "title": "Bronchial Responsiveness to Mannitol", "description": "Change in cumulative Mannitol dose in mg in patients with a positive mannitol provocation test at baseline (PD15)", "populationDescription": "The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg", "timeFrame": "Baseline and 6 weeks", "groups": [{"id": "OG000", "title": "Budesonide/Terbutaline", "description": "Budesonide once daily and terbutaline before exercise and as needed"}, {"id": "OG001", "title": "Terbutaline", "description": "Placebo budesonide once daily and terbutaline before exercise and as needed"}, {"id": "OG002", "title": "Budesonide/Formoterol", "description": "Placebo budesonide once daily and budesonide/formoterol before exercise and as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "67.26", "spread": "141.98"}, {"groupId": "OG001", "value": "-6.15", "spread": "95.10"}, {"groupId": "OG002", "value": "151.87", "spread": "141.09"}]}]}]}, {"type": "SECONDARY", "title": "Concentration of Exhaled Nitric Oxide", "populationDescription": "The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ppb", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Budesonide/Terbutaline", "description": "Budesonide once daily and terbutaline before exercise and as needed"}, {"id": "OG001", "title": "Terbutaline", "description": "Placebo budesonide once daily and terbutaline before exercise and as needed"}, {"id": "OG002", "title": "Budesonide/Formoterol", "description": "Placebo budesonide once daily and budesonide/formoterol before exercise and as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "25.9", "spread": "20.1"}, {"groupId": "OG001", "value": "35.5", "spread": "36.6"}, {"groupId": "OG002", "value": "24.4", "spread": "22.4"}]}]}]}, {"type": "SECONDARY", "title": "Use of as Needed Medication", "description": "Mean number of as needed inhalations taken before exercise", "populationDescription": "The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "number of inhalations per day", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Budesonide/Terbutaline", "description": "Budesonide once daily and terbutaline before exercise and as needed"}, {"id": "OG001", "title": "Terbutaline", "description": "Placebo budesonide once daily and terbutaline before exercise and as needed"}, {"id": "OG002", "title": "Budesonide/Formoterol", "description": "Placebo budesonide once daily and budesonide/formoterol before exercise and as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "20"}, {"groupId": "OG002", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.6", "spread": "0.2"}, {"groupId": "OG001", "value": "0.8", "spread": "0.5"}, {"groupId": "OG002", "value": "0.7", "spread": "0.5"}]}]}]}, {"type": "SECONDARY", "title": "Asthma Control Measured by a 5-item Asthma Control Questionnaire (ACQ5)", "description": "Change in overall ACQ5. ACQ5 measures asthma control and a lower values shows a better asthma control, a higher value is worse. A decrease in the ACQ5 shows an improvement during the treatment period. Range of ACQ5 is 0-5, with 0 as the best value and 5 as the worst value. Further information at www.qoltech.co.uk.", "populationDescription": "The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline e and 6 weeks", "groups": [{"id": "OG000", "title": "Budesonide/Terbutaline", "description": "Budesonide once daily and terbutaline before exercise and as needed"}, {"id": "OG001", "title": "Terbutaline", "description": "Placebo budesonide once daily and terbutaline before exercise and as needed"}, {"id": "OG002", "title": "Budesonide/Formoterol", "description": "Placebo budesonide once daily and budesonide/formoterol before exercise and as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "21"}, {"groupId": "OG002", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "0.7"}, {"groupId": "OG001", "value": "-0.2", "spread": "0.8"}, {"groupId": "OG002", "value": "-0.4", "spread": "0.7"}]}]}]}, {"type": "SECONDARY", "title": "Diary Recording of Asthma Symptoms", "description": "Asthma symptoms during days with exercise", "populationDescription": "The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent of exercise days", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Budesonide/Terbutaline", "description": "Budesonide once daily and terbutaline before exercise and as needed"}, {"id": "OG001", "title": "Terbutaline", "description": "Placebo budesonide once daily and terbutaline before exercise and as needed"}, {"id": "OG002", "title": "Budesonide/Formoterol", "description": "Placebo budesonide once daily and budesonide/formoterol before exercise and as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "20"}, {"groupId": "OG002", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "51.1", "spread": "30.5"}, {"groupId": "OG001", "value": "50.9", "spread": "36.6"}, {"groupId": "OG002", "value": "49.8", "spread": "26.1"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With an Adverse Event During the Study", "populationDescription": "The Full Analysis Set (FAS) comprises all randomized patients regardless of whether they took IP or not and for whom data had been recorded in the CRF after randomization.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Budesonide/Terbutaline", "description": "Budesonide once daily and terbutaline before exercise and as needed"}, {"id": "OG001", "title": "Terbutaline", "description": "Placebo budesonide once daily and terbutaline before exercise and as needed"}, {"id": "OG002", "title": "Budesonide/Formoterol", "description": "Placebo budesonide once daily and budesonide/formoterol before exercise and as needed"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "13"}, {"groupId": "OG002", "value": "13"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Budesonide/Terbutaline", "description": "Budesonide once daily and terbutaline before exercise and as needed", "seriousNumAffected": 0, "seriousNumAtRisk": 21, "otherNumAffected": 7, "otherNumAtRisk": 21}, {"id": "EG001", "title": "Terbutaline", "description": "Placebo budesonide once daily and terbutaline before exercise and as needed", "seriousNumAffected": 0, "seriousNumAtRisk": 22, "otherNumAffected": 10, "otherNumAtRisk": 22}, {"id": "EG002", "title": "Budesonide/Formoterol", "description": "Placebo budesonide once daily and budesonide/formoterol before exercise and as needed", "seriousNumAffected": 0, "seriousNumAtRisk": 23, "otherNumAffected": 9, "otherNumAtRisk": 23}], "otherEvents": [{"term": "Common cold", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 22}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 23}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 22}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 23}]}, {"term": "Gastroenteritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 23}]}, {"term": "Sore throat", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 23}]}, {"term": "Headache", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 22}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 23}]}, {"term": "Slight Fever", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 22}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 23}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}, {"id": "D000001250", "term": "Asthma, Exercise-Induced"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000092202", "term": "Exercise-Induced Allergies"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M4557", "name": "Asthma, Exercise-Induced", "asFound": "Exercise Induced Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M2906", "name": "Exercise-Induced Allergies", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}, {"id": "D000013726", "term": "Terbutaline"}, {"id": "D000068759", "term": "Formoterol Fumarate"}, {"id": "D000069502", "term": "Budesonide, Formoterol Fumarate Drug Combination"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000013566", "term": "Sympathomimetics"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M304", "name": "Formoterol Fumarate", "asFound": "Nicotine", "relevance": "HIGH"}, {"id": "M16496", "name": "Terbutaline", "asFound": "Temodar", "relevance": "HIGH"}, {"id": "M452", "name": "Budesonide, Formoterol Fumarate Drug Combination", "asFound": "Early Stage", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M16345", "name": "Sympathomimetics", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Repr", "name": "Reproductive Control Agents"}]}}, "hasResults": true}